Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters

Exclusion Criteria16

• CVC in place for >72 hours
• Patient requires anticoagulation for other indications
• Concomitant use of dual antiplatelet therapy
• Major bleeding event in the last 4 weeks
• Patients receiving concomitant systemic treatment with strong inhibitors of both CYP 3A4 and P-gp (such as cobicistat, ketoconazole, itraconazole, posaconazole, or ritonavir).
• Known pregnancy or plan to become pregnant in next 3 months
• Severe renal insufficiency (Creatinine clearance <30 mL/min (defined by Cockcroft-Gault) in the previous 3 months
• Documented severe liver disease (e.g., acute clinical hepatitis, chronic active hepatitis or cirrhosis) in the previous 3 months
• Known thrombocytopenia (platelet count < 50x 109/L) in the previous 3 months
• Known allergy to rivaroxaban
• Life expectancy <3 months
• History of condition at increased bleeding risk including, but not limited to:
• cerebral infarction (hemorrhagic or ischemic), active peptic ulcer disease with recent bleeding, spontaneous or acquired impairment of hemostasis in the past 4 weeks.
• Chronic hemorrhagic disorder
• Primary malignancy diagnosis of basal cell or squamous cell carcinoma of the skin only
• Refused or unable to obtain consent